Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.
Thyroid Cancer, Papillary, Hypothyroidism
About this trial
This is an interventional treatment trial for Thyroid Cancer, Papillary focused on measuring type 2 deiodinase, TSH suppression
Eligibility Criteria
Inclusion Criteria:
- Age 18-65
- Patients with Hypothyroidism after total thyroidectomy for papillary thyroid carcinoma
- Patients were informed of the study and voluntarily willing to participate.
Exclusion Criteria:
- Having depression or other mental illness
- Taking drugs that interfere with thyroid hormone absorption for other chronic diseases
- impaired liver function, defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN
- impaired renal function ,eGFR: <45 mL/min (calculated by MDRD formula)
- Recent Cardiovascular Events in a patient:
(1)Acute Coronary Syndrome (ACS) within 2 months prior to enrolment (2).Hospitalization for unstable angina or acute myocardial infarction within 2 months prior to enrolment (3)Acute Stroke or TIA within two months prior to enrolment (4)Less than two months post coronary artery revascularization 6. Congestive heart failure defined as New York Heart Association (NYHA) class IV, unstable or acute congestive heart failure.
7. Pregnant or breastfeeding women
Sites / Locations
- Yan LingRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
L-T4 therapy group
L-T4+T3 therapy group
Patients with refractory hypothyroidism still receive L-T4 therapy as usual.
Patients with refractory hypothyroidism receive L-T4+T3 therapy